The number of deaths related to Chagas disease is estimated at 10,000 to 12,500 per year.[27]World Health Organization. Chagas disease in Latin America: an epidemiological update based on 2010 estimates. Wkly Epidemiol Rec. 2015 Feb 6;90(6):33-43.
https://iris.who.int/bitstream/handle/10665/242316/WER9006_33-44.PDF?sequence=1&isAllowed=y
http://www.ncbi.nlm.nih.gov/pubmed/25671846?tool=bestpractice.com
[28]TDR. Report of the scientific working group on Chagas disease, 17-20 April 2005 [in Spanish]. Buenos Aires, Argentina; 2007.
https://iris.who.int/bitstream/handle/10665/69724/TDR_SWG_09_spa.pdf?sequence=1&isAllowed=y
[29]Moncayo A, Silveira AC. Current epidemiological trends for Chagas disease in Latin America and future challenges in epidemiology, surveillance and health policy. Mem Inst Oswaldo Cruz. 2009;104(suppl 1):17-30.
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0074-02762009000900005&lng=en&nrm=iso&tlng=en
http://www.ncbi.nlm.nih.gov/pubmed/19753454?tool=bestpractice.com
[226]Jannin J, Salvatella R, eds. Estimacion cuantitativa de la enfermedad de Chagas en las Americas. Montevideo, Uruguay: OPS/HDM/CD/425-06; 2006:28. There are an estimated 546,000 to 806,000 disability-adjusted life years lost.[227]Murray CJ, Vos T, Lozano R, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012 Dec 15;380(9859):2197-223.
http://www.ncbi.nlm.nih.gov/pubmed/23245608?tool=bestpractice.com
[228]Lee BY, Bacon KM, Bottazzi ME, et al. Global economic burden of Chagas disease: a computational simulation model. Lancet Infect Dis. 2013 Apr;13(4):342-8.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3763184
http://www.ncbi.nlm.nih.gov/pubmed/23395248?tool=bestpractice.com
[229]World Health Organization. World Health Report 2004: changing history. Geneva: WHO; 2004:120-1,126-7.
http://www.who.int/whr/2004/en/report04_en.pdf
Antiparasitic treatment is almost 100% effective in curing the disease but only if it is administered as soon as possible after infection at the onset of the acute phase. Efficacy diminishes the longer a person has been infected. Morbidity and mortality rates in patients with oral transmission are higher than in acute cases caused by other modes of transmission.[9]Shikanai-Yasuda MA, Carvalho NB. Oral transmission of Chagas disease. Clin Infect Dis. 2012 Mar;54(6):845-52.
https://academic.oup.com/cid/article/54/6/845/290317
http://www.ncbi.nlm.nih.gov/pubmed/22238161?tool=bestpractice.com
The overall prognosis among patients with the indeterminate phase is excellent.[72]Hasslocher-Moreno AM, Xavier SS, Saraiva RM, et al. Indeterminate form of Chagas disease: historical, conceptual, clinical, and prognostic aspects. Rev Soc Bras Med Trop. 2021;54:e02542021.
https://www.scielo.br/j/rsbmt/a/XdBqRnywwhwm5y3pqFF5HTH/?lang=en
http://www.ncbi.nlm.nih.gov/pubmed/34320133?tool=bestpractice.com
[134]Meymandi S, Hernandez S, Park S, et al. Treatment of Chagas disease in the United States. Curr Treat Options Infect Dis. 2018 Jun 26;10(3):373-88.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6132494
http://www.ncbi.nlm.nih.gov/pubmed/30220883?tool=bestpractice.com
From 10-20 years after the acute phase, the indeterminate form progresses to cardiomyopathy at an annual rate of 1.9%.[230]Chadalawada S, Sillau S, Archuleta S, et al. Risk of chronic cardiomyopathy among patients with the acute phase or indeterminate form of Chagas disease: a systematic review and meta-analysis. JAMA Netw Open. 2020 Aug 3;3(8):e2015072.
https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2770045
http://www.ncbi.nlm.nih.gov/pubmed/32865573?tool=bestpractice.com
Patients who have experienced acute symptomatic Chagas disease but have not received trypanocidal treatment face a higher risk of developing the cardiac form, with an estimated annual progression rate of 4.6%.[2]Nunes MCP, Beaton A, Acquatella H, et al. Chagas cardiomyopathy: an update of current clinical knowledge and management: a scientific statement from the American Heart Association. Circulation. 2018 Sep 18;138(12):e169-209.
https://www.ahajournals.org/doi/full/10.1161/CIR.0000000000000599?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed
http://www.ncbi.nlm.nih.gov/pubmed/30354432?tool=bestpractice.com
[230]Chadalawada S, Sillau S, Archuleta S, et al. Risk of chronic cardiomyopathy among patients with the acute phase or indeterminate form of Chagas disease: a systematic review and meta-analysis. JAMA Netw Open. 2020 Aug 3;3(8):e2015072.
https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2770045
http://www.ncbi.nlm.nih.gov/pubmed/32865573?tool=bestpractice.com
Cardiomyopathy is the leading cause of death in patients with the cardiac form of chronic disease, due to heart failure, cardioembolic stroke, or sudden death.[4]Dias JC, Ramos AN Jr, Gontijo ED, et al. 2 nd Brazilian Consensus on Chagas disease, 2015. Rev Soc Bras Med Trop. 2016 Dec;49Suppl 1(Suppl 1):3-60.
https://www.scielo.br/j/rsbmt/a/mNgRbrGjpwwc9dSF73PdMHt/?lang=en
http://www.ncbi.nlm.nih.gov/pubmed/27982292?tool=bestpractice.com
[13]Brazilian Ministry of Health. Brazilian consensus on Chagas disease [in Portuguese]. Rev Soc Bras Med Trop. 2005;38(suppl 3):7-29.
http://www.ncbi.nlm.nih.gov/pubmed/16416933?tool=bestpractice.com
[14]Andrade JP, Marin Neto JA, Paola AA, et al. I Latin American guidelines for the diagnosis and treatment of Chagas' heart disease: executive summary. Arq Bras Cardiol. 2011 Jun;96(6):434-42.
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0066-782X2011000600002&lng=en&nrm=iso&tlng=en
http://www.ncbi.nlm.nih.gov/pubmed/21789345?tool=bestpractice.com
[231]Saraiva RM, Mediano MFF, Mendes FS, et al. Chagas heart disease: an overview of diagnosis, manifestations, treatment, and care. World J Cardiol. 2021 Dec 26;13(12):654-75.
https://www.wjgnet.com/1949-8462/full/v13/i12/654.htm
http://www.ncbi.nlm.nih.gov/pubmed/35070110?tool=bestpractice.com
The case fatality rate in patients with reactivation is high, especially if diagnosis is delayed.[6]Shikanai-Yasuda MA, Mediano MFF, Novaes CTG, et al. Clinical profile and mortality in patients with T. cruzi/HIV co-infection from the multicenter data base of the "Network for healthcare and study of Trypanosoma cruzi/HIV co-infection and other immunosuppression conditions". PLoS Negl Trop Dis. 2021 Sep 30;15(9):e0009809.
https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0009809
http://www.ncbi.nlm.nih.gov/pubmed/34591866?tool=bestpractice.com
[8]Shikanai-Yasuda MA, de Almeida EA, López MC, et al. Chagas disease: a parasitic infection in an immunosuppressed host. Springer, Cham. 2020 Jul 21;213-34.[232]Martins-Melo FR, Alencar CH, Ramos AN Jr, et al. Epidemiology of mortality related to Chagas' disease in Brazil, 1999-2007. PLoS Negl Trop Dis. 2012;6(2):e1508.
http://www.plosntds.org/article/info%3Adoi%2F10.1371%2Fjournal.pntd.0001508
http://www.ncbi.nlm.nih.gov/pubmed/22348163?tool=bestpractice.com
Diagnosis should be made quickly, as the early administration of specific treatment increases prognosis considerably.[4]Dias JC, Ramos AN Jr, Gontijo ED, et al. 2 nd Brazilian Consensus on Chagas disease, 2015. Rev Soc Bras Med Trop. 2016 Dec;49Suppl 1(Suppl 1):3-60.
https://www.scielo.br/j/rsbmt/a/mNgRbrGjpwwc9dSF73PdMHt/?lang=en
http://www.ncbi.nlm.nih.gov/pubmed/27982292?tool=bestpractice.com
[8]Shikanai-Yasuda MA, de Almeida EA, López MC, et al. Chagas disease: a parasitic infection in an immunosuppressed host. Springer, Cham. 2020 Jul 21;213-34.
The criteria for cure are based on achieving negative serology. The time to reach negative serology varies depending on the phase of disease: from 3-5 years in acute Chagas disease; about 1 year for congenital infection; 5-10 years for recent chronic-phase disease; and ≥20 years for long-term chronic-phase disease.[175]Centers for Disease Control and Prevention. Parasites - American trypanosomiasis (also known as Chagas disease): congenital chagas disease. Jun 2021 [internet publication].
https://www.cdc.gov/parasites/chagas/health_professionals/congenital_chagas.html
[233]Alvarez MG, Bertocchi GL, Cooley G, et al. Treatment success in Trypanosoma cruzi infection is predicted by early changes in serially monitored parasite-specific T and B cell responses. PLoS Negl Trop Dis. 2016 Apr;10(4):e0004657.
https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0004657
http://www.ncbi.nlm.nih.gov/pubmed/27128444?tool=bestpractice.com
In the chronic phase, a sustainable and progressive decline of serologic titers (≥3 dilutions in serologic titers) may occur, suggesting future negative serology. At any stage of disease evolution, positive parasitologic testing indicates failure of treatment. Spontaneous cure in chronic cases of Chagas disease is usually not observed, although some cases have been registered in Costa Rica, Uruguay, and Brazil.[234]Zeledón R, Dias JC, Brilla-Salazar A, et al. Does a spontaneous cure for Chagas' disease exist? Rev Soc Bras Med Trop. 1988 Jan-Mar;21(1):15-20.[235]Francolino SS, Antunes AF, Talice R, et al. New evidence of spontaneous cure in human Chagas' disease. Rev Soc Bras Med Trop. 2003 Jan-Feb;36(1):103-7.
https://www.scielo.br/j/rsbmt/a/mL864yGPVMnVsxqVL4ZvD7q/?lang=en
http://www.ncbi.nlm.nih.gov/pubmed/12715069?tool=bestpractice.com
[236]Dias JC, Dias E, Martins-Filho OA, et al. Further evidence of spontaneous cure in human Chagas disease. Rev Soc Bras Med Trop. 2008 Sep-Oct;41(5):505-6.
https://www.scielo.br/j/rsbmt/a/5RkJswMKGFfMGYCsnhYxQHP/?lang=en
http://www.ncbi.nlm.nih.gov/pubmed/19009195?tool=bestpractice.com